

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The MRI data of the first 60 cohorts listed in Supplementary Data 8 are available at the International Neuroimaging Data-sharing Initiative (http://fcon_1000.projects.nitrc.org), Brain Genomics Superstruct Project (<https://doi.org/10.7910/DVN/25833>), Human Connectome Project (<https://www.humanconnectome.org>), MPI-Leipzig Mind-Brain-Body Project (<https://openneuro.org/datasets/ds000221>), and Age-ility Project (<https://www.nitrc.org/projects/age-ility>). The MRI data of the PKU cohort are under active use by the reporting laboratory and will be available from the corresponding author upon reasonable request. The preprocessed AHBA dataset is available at <https://doi.org/10.6084/m9.figshare.6852911>. The normalized BrainSpan Atlas dataset is available at <http://brainspan.org/static/download.html>. The neurotransmitter receptor and transporter density maps provided by the JuSpace toolbox are available at <https://github.com/juryxy/JuSpace>. The fiber length profiling dataset is available at <https://balsa.wustl.edu/study/1K3I>. The cortical thickness atrophy dataset provided by the ENIGMA Toolbox is available at <https://github.com/MICA-MNI/ENIGMA>. Numerical source data to reproduce all figure panels is available at <https://doi.org/10.6084/m9.figshare.21194128>.

Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

Reporting on sex and gender

Male 2377, female 2835.

No new data was collected for this manuscript. Sex information was provided by the existing datasets.

Population characteristics

Age and sex data provided by existing dataset were used in this manuscript. Age: 18-36 years. 2377 males, 2835 females.

Recruitment

Recruitment is not appropriate to this study, because no new data was collected for this manuscript.

Ethics oversight

No new data was collected for this manuscript. We collected rsfMRI dataset from public data-sharing platforms and existing in-house cohorts, which consists of 73 cohorts from Asia, Europe, North America, and Australia. Data of each cohort were collected with participants' written informed consent and with approval by the respective local institutional review boards.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

No a-prior sample size was calculated, but we included a large-sample resting-state fMRI dataset of 5,212 healthy young adults (aged 18–36 years) in this manuscript. Our validation analysis in this manuscript demonstrated that resting-state fMRI dataset of 5,212 subjects were adequate to obtain highly reproducible results.

Data exclusions

For MRI data of the all 73 cohorts, we used strict and uniform inclusion criteria with regard to structural abnormality and head motion. Specifically, we first reviewed T1-weighted structural MRI data for all participants and excluded subjects with identifiable lesion or structural abnormality (e.g., regional atrophy and posterior cranial fossa arachnoid cyst). Then, during resting-state fMRI data preprocessing, we excluded subjects with significant head motion (translation above 3 mm or rotation above 3° in any direction) and subjects with more than 25% interpolated volumes after head motion scrubbing. To reduce the potential effects of development and aging on our results, we restricted our analysis to healthy young adults (aged 18–36 years). To ensure sufficient statistical power, twelve cohorts were discarded due to having fewer than 10 participants that passed quality controls. After these stringent quality controls, we included preprocessed resting-state fMRI data of 5,212 healthy young adults (2,377 males) from 61 cohorts in the final analysis.

Replication

Reproducibility of main findings was ensured by extensive validation analysis of analysis parameters, analysis models and tools, and datasets.

Randomization

Randomization is not appropriate to this study, because no new data was collected for this manuscript.

Blinding

Blinding is not appropriate to this study, because no new data was collected for this manuscript.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

- n/a Involved in the study
- Antibodies
- Eukaryotic cell lines
- Palaeontology and archaeology
- Animals and other organisms
- Clinical data
- Dual use research of concern

Methods

- n/a Involved in the study
- ChIP-seq
- Flow cytometry
- MRI-based neuroimaging

Magnetic resonance imaging

Experimental design

- Design type
- Design specifications
- Behavioral performance measures

Acquisition

- Imaging type(s)
- Field strength
- Sequence & imaging parameters
- Area of acquisition
- Diffusion MRI Used Not used

Preprocessing

- Preprocessing software https://www.fil.ion.ucl.ac.uk/spm/software/spm12) and GRETNA v2.0.0 (<https://www.nitrc.org/projects/gretna>). Functional MRI data were spatially smoothed using a 6-mm full-width at half-maximum Gaussian kernel."/>
- Normalization
- Normalization template
- Noise and artifact removal
- Volume censoring

Statistical modeling & inference

- Model type and settings
- Effect(s) tested
- Specify type of analysis: Whole brain ROI-based Both
- Statistic type for inference (See [Eklund et al. 2016](#))

Correction

Permutation and Bonferroni correction.

Models & analysis

- n/a | Involved in the study
- Functional and/or effective connectivity
 - Graph analysis
 - Multivariate modeling or predictive analysis

Functional and/or effective connectivity

Pearson's correlation.

Graph analysis

Functional connectivity strength.

Multivariate modeling and predictive analysis

We trained supervised machine learning classifiers based on XGBoost and SVM to distinguish connectome hubs from non-hubs using 10,027 genes¹ transcriptomic features from the preprocessed AHBA dataset. The sensitivity, specificity, and accuracy rate of the classifier were stably estimated by repeating the training and testing procedure 1,000 times. Cross-validation was used to obtain the optimal prediction model.